This invention relates to a compound for treating thrombotic diseases. Specifically, this invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, or its
enantiomer,
diastereomer, transtransferase,
racemic mixture, polymorph thereof, solvate thereof, or isotopically labeled derivative thereof. The compound of this invention specifically binds to the SH3 domain
protein of Src
kinase, interfering with the binding of
integrin αIIbβ3 to Src
kinase, thereby selectively inhibiting outward-to-inward
signal transduction without affecting inward-to-outward
signal transduction. This allows the compound of this invention to exert
antithrombotic effects without affecting normal physiological
hemostasis, avoiding bleeding side effects, and thus becoming a new generation of effective drugs for the prevention and treatment of
thrombosis-related cardiovascular and cerebrovascular diseases.